IntelGenx, a Canadian drug delivery company focusing on oral drug delivery, has announced that it has received a notice of allowance from the US Patent and Trademark Office for its Patent Application Serial No. 11/647,033 entitled ‘Multilayer tablet’ which covers the technology used in our hypertension product currently under development.
A second NOA has been received for US Patent Application Serial No. 11/782,838 entitled 'Controlled-release pharmaceutical tablets' which is related to the drug delivery technology used in Forfivo XL, IntelGenx' first FDA-approved product currently commercialized in the US.
These two NOA's conclude the examination of each US patent application and will result in the issuance of two US patents after administrative processes are completed.
IntelGenx president and CEO Rajiv Khosla noted these two additional NOA's in the US represent yet another important expansion of the company's patent estate as well as demonstrating the innovative design of our drug delivery technologies.
"Our goal is to protect the innovation and commercial potential of the products developed at IntelGenx and these NOA's further strengthen our proprietary position," Khosla added.
